Recent News
Orphagen Pharmaceuticals Receives NIH Funding Award to Advance a Novel Drug for Inflammatory Bowel Disease
Funding to support preclinical development of Orphagen’s lead IBD candidate, OR-812, a first-in-class, small molecule inhibitor of the retinoic acid receptor alpha (RARα) SAN DIEGO--(BUSINESS WIRE)--Orphagen Pharmaceuticals, Inc., a biotech company pioneering the...
The Texas State Cancer Agency (CPRIT) Announces a Product Development Award to Support a Phase 1 Clinical Trial for OR-449, a First-in-Class Therapy for Oncology
The Cancer Prevention & Research Institute of Texas (CPRIT) announced today that it plans to award Orphagen a $10.2 M product development grant over three years to partially fund the final steps towards IND filing and a Phase 1 clinical trial of OR-449, a novel...
Orphagen Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for OR-449 for the Treatment of Pediatric Adrenocortical Carcinoma
SAN DIEGO--(BUSINESS WIRE)--Orphagen Pharmaceuticals, Inc., a biotech company pioneering the screening, discovery, and development of small molecule ligands that modulate orphan or unexplored members of the nuclear receptor family, today announced that the U.S. Food...
Orphagen Pharmaceuticals Presents Data on Downstream Targets of SF-1 Antagonist OR-449 at ENDO 2022
SAN DIEGO, June 11, 2022 - Orphagen Pharmaceuticals, an early-stage biopharmaceutical company focused on developing and commercializing novel therapies for cancer and other serious diseases with significant unmet need, today announced that additional data from its...
Orphagen Pharmaceuticals Presents Preclinical Efficacy Data at AACR 2022 on OR-449, a First-in-Class Steroidogenic Factor 1 Inhibitor, for the Treatment of Leydig Cell Tumors
SAN DIEGO, April 8, 2022 -- Orphagen Pharmaceuticals Inc., a biotech company pioneering the screening, discovery, and development of small molecule ligands that modulate orphan or unexplored members of the nuclear receptor family, today announced a late-breaking...